April 28th 2025
Smoking prevalence is projected to decline by 2035, yet health consequences persist due to slower reductions among older adults.
Dr Donna Fitzsimons: “Doctor Knows Best” Mindset Wanes as Patients Become More Self-Educated
September 20th 2023Patients now have higher expectations of us health care professionals, and we have to meet those expectations, said Donna Fitzsimons, PhD, FESC, professor of nursing at the School of Nursing and Midwifery, Queen's University Belfast.
Watch
Dr Ryan Haumschild Discusses Payer, Provider Perspectives on Prior Authorization in Rare Diseases
September 19th 2023Ryan Haumschild, PharmD, MS, MBA, director of pharmacy at Emory Winship Cancer Institute, shares his unique perspectives as both a provider and payer on the use of prior authorizations (PAs) and "Gold Cards" in patients with rare diseases.
Watch
Relative Benefit in Survival, Reduction in TE/MAVE Risk With Eculizumab for Patients With PNH
September 19th 2023When patients with paroxysmal nocturnal hemoglobinuria (PNH) received eculizumab, survival rates increased and thromboembolic events/major adverse vascular events (TE/MAVE) decreased.
Read More
Dr Kristine Slam: Value-Based Care in Breast Cancer Requires Collaboration
September 19th 2023In this interview from our Institute for Value-Based Medicine® event, held in partnership with the Zangmeister Cancer Center of Columbus, Ohio, on September 14, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the benefits of value-based care in the breast cancer space.
Watch
What We’re Reading: Mental Health AI Tools; Obesity Drug Shortages; Health Worker Mask Guidelines
September 18th 2023Artificial intelligence (AI) tools offer potential solutions to the growing demand in mental health; patients face weight loss drug shortages and insurance complications; updated mask guidelines cause worry among health care workers.
Read More
Dr Milind Desai on VALOR-HCM: Primary and Secondary Effects Are Sustained While on Mavacamten
September 16th 2023Secondary effects not only improved past 16 weeks, but showed a sustained improvement at week 56 of mavacamten, said Milind Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and vice chair of education at the Heart, Vascular & Thoracic Institute, Cleveland Clinic.
Watch
Diet and Exercise Intervention Associated With Better pCR in TNBC or HR+, HER2– BC
September 16th 2023Despite seeming to elicit more pathological complete responses (pCRs) in patients with hormone receptor–positive (HR+), HER2-negative triple-negative breast cancer (BC) receiving neoadjuvant chemotherapy, diet and exercise did not affect relative dose intensity.
Read More
Cabozantinib Plus Atezolizumab Significantly Improves PFS in Metastatic CRPC
September 16th 2023Combination treatment with cabozantinib and atezolizumab did not produce any new safety signals in the treatment of those with metastatic castration-resistant prostate cancer in the phase 3 CONTACT-02 trial.
Read More
Measuring Continuity of Care for Diabetes: Which Visits to Include?
This study examined how inclusion of different provider specialties affected Continuity of Care Index values, year-to-year stability, and association with emergency department visits.
Read More
Dr Zachary Cox: Early Dapagliflozin Modestly Improves Diuresis, Decongestion for Patients With ADHF
September 14th 2023Despite not reaching statistical significance, findings from DICTATE-AHF show early dapagliflozin improved decongestion and led to earlier hospital discharge for patients with acute decompensated heart failure, explained Zachary Cox, PharmD, professor at Lipscomb University College of Pharmacy.
Watch
Expert Panel Addresses Prostate Cancer Misconceptions, Importance of Screening
September 14th 2023Panelists from the American College of Surgeons (ACS) and the American Urological Association spread awareness about the realities of prostate cancer, the importance of screening, and ways for men to approach their health concerns and prevention.
Read More
Atezolizumab Misses PFS End Point in Recurrent Epithelial Ovarian Cancer
September 12th 2023Results from ATLANTE/ENGOT-ov29 show that atezolizumab did not significantly improve progression-free survival (PFS) compared with placebo plus bevacizumab for patients with platinum-sensitive ovarian cancer.
Read More
What We’re Reading: Updated COVID-19 Vaccines; National Blood Shortages; Lack of Doctor Diversity
September 12th 2023FDA approves updated COVID-19 booster vaccines; low donor turnout and climate disasters result in a national blood shortage; minority patients discouraged by lack of doctor diversity.
Read More